This was the first positive ADC trial in the adjuvant setting in breast cancer and established T-DM1 as the preferred adjuvant therapy for HER2+ breast cancer patients with residual disease after completion of neoadjuvant chemotherapy [11]. The gene discussed is ERBB2; the disease is breast carcinoma.